Effect of Dupilumab on the Host-Microbe interface in Atopic Dermatitis

  • STATUS
    Recruiting
  • participants needed
    99
  • sponsor
    NIH
Send
Updated on 19 February 2024

Summary

Atopic dermatitis is a disease with dry, scaly, itchy skin. People with AD often have problems with repear bacterial and viral skin infections. There repeat infections are often caused by a specific bacteria known as. Staph aureus, or just staph. People with chronic AD often use long term topical or oral treatments to help control their disease symptoms. Using these medications over long periods of time can have effects on the body. For this reason, new treatment options are being researched, especially for patients whose symptoms are not controlled by existing medications.

Description

Dupilmab is a new treatment recently approved by the FDA. It is for the treatment of moderate-to-severe AD in adults whose AD symptoms are not well controlled with topical medications. The purpose of this study is to determine how dupilmab affects the amount of bacteria on the skin, the skin's water loss and the immune symptom.


This study will enroll participants between 18-75 yrs old. All participants will have chronic moderate to severe atopic dermatitis. 

FAQ


Details
Condition atopic dermatitius,skin,dermatology
Age 18years - 75years
Clinical Study IdentifierTX6256
SponsorNIH
Last Modified on19 February 2024

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.